Nexlizet Prices — US Pharmacy Cost vs Canada

At the US pharmacies in our data, the lowest listed discount-card price for Nexlizet is around $392.46. Prices vary by pharmacy, dosage, and pack size, so use the table above to compare specific options near you.

Canadian pharmacy listings in our data show Nexlizet priced from about $0.770 per tablet (converted to USD), before shipping. Pack size and pharmacy both affect the final total — see the Canada pricing table for specifics.

Drug pricing is set separately in each country through different negotiation, regulatory, and distribution systems, so the same medication can legitimately carry different price tags on either side of the border. Check the comparison table above for the specific numbers on Nexlizet.

Generic and brand-name pricing for Nexlizet is broken out in the tables above where both exist in our data. Generic versions are typically the lower-cost option, but availability depends on the specific formulation and dosage.

Insurance coverage for Nexlizet is not guaranteed and varies by plan. If your plan includes it on its formulary, you will typically pay a copay or coinsurance, which is usually less than the full retail price. The specific amount you pay depends on your plan's benefits, deductible status, and pharmacy tier. Your pharmacist or insurance provider can give you the most accurate estimate of your out-of-pocket costs.

Coverage for Nexlizet under Medicare Part D or Medicare Advantage plans depends on the individual plan's formulary. Some plans may cover it, while others may not, and costs like copays will vary. If you have Medicare, you should review your plan's drug list or speak with your plan administrator for details. For those without coverage or facing high out-of-pocket costs, exploring prescription discount programs may provide an alternative way to save on the medication.

No, Nexlizet is currently only available as a brand-name medication. It is manufactured by Esperion, and a generic version containing the same active ingredients (bempedoic acid and ezetimibe) is not on the market. Generic alternatives typically become available only after the brand-name drug's patent expires.